{"schema_version":"1","generated_at":"2026-11-04T09:40:37.789Z","data_as_of":"2026-11-03","url":"https://www.findmykol.com/kol/felicia-cao","json_url":"https://www.findmykol.com/kol/felicia-cao/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"felicia-cao","name":"Felicia Cao","credential":"MD","title":"Assistant Professor","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of North Carolina Hospitals","institution_url":"https://www.findmykol.com/institution/university-of-north-carolina-hospitals","city":"Chapel Hill","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1063973154","orcid":"0009-0006-5587-3994","openalex":"A5022742038"},"summary":"Felicia Cao is Assistant Professor at University of North Carolina Hospitals. OpenAlex indexes 23 publications with 247 citations (h-index 8); ClinicalTrials.gov lists 1 registered study with this person as an investigator.","overview":{"text":"Felicia Cao, MD, PHD, is Assistant Professor at University of North Carolina Hospitals. The public record shows 23 publications with 247 citations (h-index 8), centered on CAR-T cell therapy research, Immunotherapy and Immune Responses, Immunodeficiency and Autoimmune Disorders. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 3 companies.","bullets":["Most recent indexed publication: 2025 · Open forum infectious diseases","Top research focus: CAR-T cell therapy research","1 registered trials on ClinicalTrials.gov","Open Payments reporting from 3 companies"],"generated_at":"2026-11-03"},"focus":{"indications":[{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Acromegaly","therapeutic_area":"Endocrinology/Metabolic","trials":0,"topics":0,"strength":1},{"label":"Osteoporosis","therapeutic_area":"Endocrinology/Metabolic","trials":0,"topics":0,"strength":1},{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1}],"research_topics":["CAR-T cell therapy research","Immunotherapy and Immune Responses","Immunodeficiency and Autoimmune Disorders","Neutropenia and Cancer Infections","Hematopoietic Stem Cell Transplantation"],"drugs_studied":{"total":4,"shown":3,"withheld":1,"rows":[{"name":"Carvykti","generic":"Ciltacabtagene autoleucel","trials":0,"payments":2,"publications":0,"mentions":2},{"name":"Brukinsa","generic":"Zanubrutinib","trials":0,"payments":1,"publications":0,"mentions":1},{"name":"Talvey","generic":"Talquetamab","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":4,"shown":3,"withheld":1,"rows":[{"name":"BeOne Medicines USA, Inc.","trials":0,"payments":1,"mentions":1},{"name":"Janssen Scientific Affairs, LLC","trials":0,"payments":1,"mentions":1},{"name":"Legend Biotech USA Inc.","trials":0,"payments":1,"mentions":1}]}},"scholarship":{"works_count":23,"cited_by_count":247,"h_index":8,"i10_index":8,"pubmed_count":2,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT05366179","title":"Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc","phase":"PHASE1","status":"RECRUITING","role":"Investigator","sponsor":"UNC Lineberger Comprehensive Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT05366179","trial_url":"https://www.findmykol.com/trial/NCT05366179"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2025,"last":2025},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"BeOne Medicines USA, Inc.","program_year":2025,"amount_usd":127.59,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063973154"},{"payer":"Janssen Scientific Affairs, LLC","program_year":2025,"amount_usd":81.89,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063973154"},{"payer":"Legend Biotech USA Inc.","program_year":2025,"amount_usd":69.37,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063973154"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1063973154","source":"payments"},"prescribing":{"data_year":2021,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cardiovascular","share_pct":70.7,"classes_total":2,"classes":[{"class":"ACE inhibitor","setting":"prescribed","share_pct":43.9,"drugs":[{"name":"Lisinopril","share_pct":100}],"max_beneficiaries":null},{"class":"Aldosterone antagonist (MRA)","setting":"prescribed","share_pct":26.8,"drugs":[{"name":"Spironolactone","share_pct":100}],"max_beneficiaries":null}]},{"area":"Hormonal (systemic)","share_pct":29.3,"classes_total":1,"classes":[{"class":"l-Thyroxine","setting":"prescribed","share_pct":29.3,"drugs":[{"name":"Levothyroxine Sodium","share_pct":100}],"max_beneficiaries":null}]}],"source":"medicare"},"funding":{"award_count":0,"rows_total":4,"shown":3,"withheld":1,"rows":[{"project":"F30CA203270","title":"A CD47-blocking oncolytic vaccinia virus for cancer therapy","fiscal_year":2019,"amount_usd":13160,"organization":"BAYLOR COLLEGE OF MEDICINE","source_url":"https://reporter.nih.gov/quickSearch/F30CA203270"},{"project":"F30CA203270","title":"A CD47-blocking oncolytic vaccinia virus for cancer therapy","fiscal_year":2018,"amount_usd":44524,"organization":"BAYLOR COLLEGE OF MEDICINE","source_url":"https://reporter.nih.gov/quickSearch/F30CA203270"},{"project":"F30CA203270","title":"A CD47-blocking oncolytic vaccinia virus for cancer therapy","fiscal_year":2017,"amount_usd":44044,"organization":"BAYLOR COLLEGE OF MEDICINE","source_url":"https://reporter.nih.gov/quickSearch/F30CA203270"}],"source":"grants"},"congress":{"count":3,"years":{"first":2012,"last":2025},"societies":["AACR","ASH"],"shown":3,"withheld":0,"rows":[{"title":"Rehabilitation needs and clinical associations post CAR T-cell therapy: A retrospective analysis","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-4524","source_url":"https://doi.org/10.1182/blood-2025-4524","status":"verified"},{"title":"Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant","society":"ASH","meeting":"ASH Annual Meeting","year":2020,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2020-141151","source_url":"https://doi.org/10.1182/blood-2020-141151","status":"verified"},{"title":"Abstract 3726: Allyl isothiocyanate (AITC), a naturally occurring compound, combined with platinum-based therapies enhances apoptosis in vitro, and inhibits lung tumor growth in vivo","society":"AACR","meeting":"AACR Annual Meeting","year":2012,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2012-3726","source_url":"https://doi.org/10.1158/1538-7445.am2012-3726","status":"verified"}],"source":"congress"},"publications":{"total":2,"shown":2,"withheld":0,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.","year":2025,"journal":"Open forum infectious diseases","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40980578/","status":"verified"},{"title":"Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults.","year":2024,"journal":"medRxiv : the preprint server for health sciences","types":["Journal Article","Preprint"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39040188/","status":"verified"}],"most_cited":{"total":23,"shown":5,"withheld":18,"rows":[{"title":"Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma","year":2018,"cited_by_count":122,"type":"article","source_url":"https://doi.org/10.1016/j.omtm.2018.01.009"},{"title":"Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells","year":2020,"cited_by_count":21,"type":"article","source_url":"https://doi.org/10.1002/acg2.99"},{"title":"Generalized metabolic bone disease and fracture risk in Rothmund-Thomson syndrome","year":2017,"cited_by_count":17,"type":"article","source_url":"https://doi.org/10.1093/hmg/ddx178"},{"title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two","year":2016,"cited_by_count":17,"type":"article","source_url":"https://doi.org/10.1186/s40425-016-0173-6"},{"title":"Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo.","year":2015,"cited_by_count":15,"type":"article","source_url":"https://openalex.org/A5022742038"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Natalie Sophia Grover","coauthored_works":5},{"name":"Melody Smith","coauthored_works":4,"profile_url":"https://www.findmykol.com/kol/melody-smith"},{"name":"Gianpietro Dotti","coauthored_works":4}],"source":"works"},"recognition":{"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"University of North Carolina at Chapel Hill (Fellow) [past]","source_url":"https://orcid.org/0009-0006-5587-3994","status":"verified","collected_at":"2026-11-03"}]}},"similar":[{"name":"Henry Lesesne","slug":"henry-lesesne","institution":"University of North Carolina Hospitals","specialty":"Gastroenterology","url":"https://www.findmykol.com/kol/henry-lesesne","json_url":"https://www.findmykol.com/kol/henry-lesesne/profile.json"},{"name":"Brianna Frame","slug":"brianna-frame","institution":"University of North Carolina Hospitals","specialty":"Obstetrics & Gynecology","url":"https://www.findmykol.com/kol/brianna-frame","json_url":"https://www.findmykol.com/kol/brianna-frame/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"funding":1,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-03"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-03"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2025 to 2025","collected_at":"2026-11-03"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2021},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-03"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-03"}},"methodology_url":"https://www.findmykol.com/about#methodology"}